by Sarah Linley | Sep 23, 2024 | Pharmaceutical Research
Alzamend Neuro is partnering with Massachusetts General Hospital to conduct a Phase 2 clinical trial of AL001, an oral therapy being developed for dementia related to Alzheimer’s disease.
by Sarah Linley | Sep 23, 2024 | Pharmaceutical Research
Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease. Preclinical testing and proof-of-concept being lead by inventor Dr. Christine Denny of Columbia University. In a press release published Jan. 24,...
